With the advent of our understanding of PCa biology from bedside, genomics, and molecular imaging techniques, it is imminent that our current theragnostic schemes, including the diagnostic modalities, the estimation of cancer progression from indolent to malignant status and therapeutic responses, and the drugs that are used to target non-AR signaling, including DNA repair defects, should be revised and improved. This evidence concerns the gene AR and cancer.